Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Diabetes

Free Subscription Articles published in J Am Coll Cardiol Retrieve available abstracts of 53 articles: HTML format

Single Articles

December 2025
1. DAS SR, Bonaca MP, Creager MA, Maruthur N, et al
   Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement: A Report of the American College of Cardiology.
   J Am Coll Cardiol. 2025 Dec 17:S0735-1097(25)10282.
   PubMed     Abstract available
   
   
   November 2025
2. LEE HH, Crawford EB, Cho SMJ, Krawisz AK, et al
   Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.
   J Am Coll Cardiol. 2025 Nov 26:S0735-1097(25)09917.
   PubMed     Abstract available
   
   
   
3. VERMA S, Catarig AM, Houlind K, Ludvik B, et al
   Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
   J Am Coll Cardiol. 2025;86:1843-1857.
   PubMed     Abstract available
   
   
   
4. OSTROMINSKI JW, Neuen BL, Claggett BL, Filippatos G, et al
   Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 Diabetes.
   J Am Coll Cardiol. 2025 Nov 18:S0735-1097(25)10071.
   PubMed    
   
   
   September 2025
5. PACKER M, Lam CSP, Butler J, Zannad F, et al
   Is Type 2 Diabetes a Modifiable Risk Factor for the Evolution and Progression of Heart Failure With a Preserved Ejection Fraction?
   J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07341.
   PubMed     Abstract available
   
   
   
6. KRUMHOLZ HM, Inzucchi SE
   Beyond Adiposity: Embracing Complexity in Diabetes-Associated HFpEF.
   J Am Coll Cardiol. 2025 Sep 17:S0735-1097(25)07385.
   PubMed    
   
   
   
7. KANG D, Choi KH, Kim JH
   Statins in Type 1 Diabetes: Bridging the Evidence Gap With Target Trial Emulation.
   J Am Coll Cardiol. 2025;86:810-812.
   PubMed    
   
   
   
8. BLAIS JE, Yan VKC, Chan EWY, Wong ICK, et al
   Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
   J Am Coll Cardiol. 2025;86:797-809.
   PubMed     Abstract available
   
   
   
9. PACKER M, Zile MR, Kramer CM, DiMaria JM, et al
   Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
   J Am Coll Cardiol. 2025;86:696-707.
   PubMed     Abstract available
   
   
   August 2025
10. GALLI M, Benenati S, Laudani C, Simeone B, et al
    Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07492.
    PubMed     Abstract available
    
    
    May 2025
11. AMINORROAYA A, Oikonomou EK, Biswas D, Jastreboff AM, et al
    Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.
    J Am Coll Cardiol. 2025;85:1858-1872.
    PubMed     Abstract available
    
    
    
12. HO JE, Chen ZZ, Lau ES
    Insulin Resistance and Diabetes in HFpEF: Bystander or Instigator?
    J Am Coll Cardiol. 2025;85:1789-1791.
    PubMed    
    
    
    
13. REDDY YNV, Frantz RP, Hemnes AR, Hassoun PM, et al
    Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025;85:1774-1788.
    PubMed     Abstract available
    
    
    April 2025
14. BORROWMAN JD, Huang X, Petito LC, Perak AM, et al
    Prepregnancy Adiposity, Adverse Pregnancy Outcomes, and Cardiovascular Disease Risk in Midlife.
    J Am Coll Cardiol. 2025;85:1536-1546.
    PubMed     Abstract available
    
    
    December 2024
15. SPERLING LS
    The "Ticking Clock" of Impending Diabetes: Cause for Concern or Window of Opportunity?
    J Am Coll Cardiol. 2024;84:2260-2263.
    PubMed    
    
    
    
16. GYLDENKERNE C, Kahlert J, Thrane PG, Olesen KKW, et al
    2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study.
    J Am Coll Cardiol. 2024;84:2251-2259.
    PubMed     Abstract available
    
    
    November 2024
17. SANTOS-PARDO I, Andersson Franko M, Nystrom T
    Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e321.
    PubMed    
    
    
    
18. LIU C, Li X, Cong H
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024;84:e319-e320.
    PubMed    
    
    
    
19. WARRAICH HJ, Patrick-Lake B, Saha A, Rashid L, et al
    Digital Health Technologies for Cardiometabolic Disease and Diabetes: A Perspective From the U.S. Food and Drug Administration.
    J Am Coll Cardiol. 2024 Nov 19:S0735-1097(24)10028.
    PubMed    
    
    
    
20. PATEL KV, Chunawala Z, Verma S, Segar MW, et al
    Intensive lifestyle intervention, cardiac biomarkers, and cardiovascular outcomes in diabetes: LookAHEAD cardiac biomarker ancillary study.
    J Am Coll Cardiol. 2024 Nov 5:S0735-1097(24)10417.
    PubMed     Abstract available
    
    
    September 2024
21. MENTZ RJ, Kittipibul V
    Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure: Fighting an Uphill Battle.
    J Am Coll Cardiol. 2024;84:1089-1091.
    PubMed    
    
    
    
22. BHATT AS, Bhatt DL, Steg PG, Szarek M, et al
    Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    J Am Coll Cardiol. 2024;84:1078-1088.
    PubMed     Abstract available
    
    
    
23. EVERETT BM, Wexler DJ
    Finding Truth in Observational and Interventional Studies in Diabetes and Cardiovascular Disease.
    J Am Coll Cardiol. 2024;84:918-920.
    PubMed    
    
    
    
24. KHERA R, Aminorroaya A, Dhingra LS, Thangaraj PM, et al
    Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM.
    J Am Coll Cardiol. 2024;84:904-917.
    PubMed     Abstract available
    
    
    August 2024
25. MANUBOLU VS, Lakshmanan S, Kinninger A, Ahmad K, et al
    Effect of Semaglutide on Epicardial Adipose Tissue in Type 2 Diabetes: Insights From the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) Randomized Trial.
    J Am Coll Cardiol. 2024;84:865-867.
    PubMed    
    
    
    
26. NEUEN BL, Ostrominski JW, Claggett B, Beldhuis IE, et al
    Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08155.
    PubMed    
    
    
    
27. PRATLEY RE, Tuttle KR, Rossing P, Rasmussen S, et al
    Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
    J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08116.
    PubMed     Abstract available
    
    
    
28. NEUEN BL, Solomon SD
    Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:709-711.
    PubMed    
    
    
    
29. EDMONSTON D, Mulder H, Lydon E, Chiswell K, et al
    Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:696-708.
    PubMed     Abstract available
    
    
    
30. SHIN JI, Xu Y, Chang AR, Carrero JJ, et al
    Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
    J Am Coll Cardiol. 2024;84:683-693.
    PubMed     Abstract available
    
    
    
31. OSTROMINSKI JW, Jemma Cho SM, Vaduganathan M, Honigberg MC, et al
    Cardiorenal Outcomes in Middle-Aged and Older Adults With Type 1 and Type 2 Diabetes.
    J Am Coll Cardiol. 2024 Aug 7:S0735-1097(24)07747.
    PubMed    
    
    
    
32. INZUCCHI SE, Arai AE
    Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes.
    J Am Coll Cardiol. 2024;84:558-560.
    PubMed    
    
    
    
33. CHOWDHARY A, Thirunavukarasu S, Joseph T, Jex N, et al
    Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.
    J Am Coll Cardiol. 2024;84:540-557.
    PubMed     Abstract available
    
    
    July 2024
34. MARINHO LL, Everett BM, Aday AW, Visseren FLJ, et al
    Effect of Pemafibrate on Diabetic Foot Ulceration and Gangrene: An Exploratory Analysis From PROMINENT.
    J Am Coll Cardiol. 2024;84:408-410.
    PubMed    
    
    
    
35. BABER U
    Stent Failure After Percutaneous Coronary Intervention in Diabetes Mellitus: Does Glycemic Control Matter?
    J Am Coll Cardiol. 2024;84:273-275.
    PubMed    
    
    
    
36. GUGLIN M, Hillerson D
    Exploring Racial and Ethnic Differences in Diabetic Cardiomyopathy: The Physical Burden of Health Disparities.
    J Am Coll Cardiol. 2024;84:244-246.
    PubMed    
    
    
    
37. LOPEZ J, Liu Y, Butler J, Del Prato S, et al
    Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.
    J Am Coll Cardiol. 2024;84:233-243.
    PubMed     Abstract available
    
    
    June 2024
38. VERMA S, Butler J, Borlaug BA, Davies M, et al
    Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials.
    J Am Coll Cardiol. 2024 Jun 19:S0735-1097(24)07445.
    PubMed     Abstract available
    
    
    
39. PINNEY SP, Costanzo MR
    As Good as it Gets: SGLT2 Inhibitors in Cardiac Amyloidosis.
    J Am Coll Cardiol. 2024;83:2423-2425.
    PubMed    
    
    
    
40. LALA A, Mentz RJ, Santos-Gallego CG
    The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure?
    J Am Coll Cardiol. 2024 Jun 12:S0735-1097(24)07407.
    PubMed    
    
    
    May 2024
41. SANTOS-PARDO I, Andersson Franko M, Lagerqvist B, Ritsinger V, et al
    Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus.
    J Am Coll Cardiol. 2024 May 7:S0735-1097(24)06933.
    PubMed     Abstract available
    
    
    April 2024
42. BONACA MP, Bhatt DL, Simon T, Fox KM, et al
    Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
    J Am Coll Cardiol. 2024;83:1627-1636.
    PubMed     Abstract available
    
    
    
43. KITTIPIBUL V, Cox ZL, Chesdachai S, Fiuzat M, et al
    Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2024;83:1568-1578.
    PubMed     Abstract available
    
    
    
44. WONG ND, Fan W, Hu X, Ballantyne C, et al
    Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.
    J Am Coll Cardiol. 2024;83:1511-1525.
    PubMed     Abstract available
    
    
    
45. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    PubMed    
    
    
    
46. PACKER M
    SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
    J Am Coll Cardiol. 2024;83:1399-1402.
    PubMed    
    
    
    
47. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    PubMed     Abstract available
    
    
    
48. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    PubMed     Abstract available
    
    
    
49. COSTANZO MR, Januzzi JL
    Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
    J Am Coll Cardiol. 2024;83:1307-1309.
    PubMed    
    
    
    
50. JANUZZI JL JR, Butler J, Del Prato S, Ezekowitz JA, et al
    Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.
    J Am Coll Cardiol. 2024 Apr 3:S0735-1097(24)06613.
    PubMed     Abstract available
    
    
    March 2024
51. CHATUR S, Vaduganathan M, Claggett B, Solomon SD, et al
    Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e89.
    PubMed    
    
    
    
52. OHSHIRO Y
    Rethinking eGFR Comparisons in SGLT2 Inhibitor Research.
    J Am Coll Cardiol. 2024;83:e87.
    PubMed    
    
    
    
53. HANSEN MK, Olesen KKW, Gyldenkerne C, Thrane PG, et al
    Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
    J Am Coll Cardiol. 2024;83:956-958.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.